Royalty Provisions. Upon receipt of an invoice from the Licensor, Licensee agrees to pay the Licensor a royalty equal to [___ percent (__%) of Revenues generated from sales of the Licensed Products by the Licensee in the Territory.]
Royalty Provisions. A. The Guaranteed Minimum Royalty per calendar year of ten thousand US Dollars (USD 10,000.00) is eliminated. Licensee shall pay Licensor a Guaranteed Minimum Royalty per month of five hundred US Dollars (USD 500.00) beginning with the month of March 2010. The Royalty Rate continues to be twenty five percent (25%) of all membership and advertising revenues.
B. The Guaranteed Minimum Royalty per month shall be due and payable on the first day of every month for the then current month. Any Royalties owed in addition to the Guaranteed Minimum Royalty for any particular month are due by the end of the following month.
C. The Royalty owed Licensor shall be calculated on a monthly calendar basis (Royalty Period). The Licensee's Net Sales shall be processed through its own payment processor and deposited into its bank account.
D. For each Royalty Period, Licensee shall provide Licensor with a written royalty statement in a form acceptable to Licensor. Such royalty statement shall be certified as accurate by a duly authorized officer of Licensee and shall include reportable sales for each applicable period. Such statements shall be furnished to Licensor regardless of whether any sales were made during the Royalty Period or whether any actual Royalty was owed.
Royalty Provisions. LICENSEE agrees to pay to LICENSOR:
a. An initial fee of [TBD], payable within 30 days following the execution of this License.
b. A minimum royalty of [TBD], payable within 30 days following the anniversary date of this License, or [TBD] percent of the gross sales price of product sold commercially, i.e. for use other than by or on behalf of the Federal Government, that incorporates any allowed product claims of LICENSED INVENTION or is produced by the method of any allowed method claims of LICENSED INVENTION, payable within 30 days following the anniversary date of this License, whichever is greater. Gross sales price shall mean actual invoiced sales price free of transfer and bank fees and free of any taxes or other deductions.
c. [TBD] of any sublicense revenue received from sublicensing of the LICENSED INVENTION due within 30 days following the receipt of such sublicense revenue by LICENSEE.
Royalty Provisions. The royalty provisions of the Agreements are amended as follows:
a. Clinical Diagnostics Agreement
i. All monies already paid to Chiron pursuant to the Clinical Diagnostics Agreement shall be retained by Chiron and are non-refundable, including, without limitation, the Ten Million United States Dollars (USD$10,000,000) U.S. Licensing Fee, any royalties for sales made prior to January 1, 2001, and any royalties for sales made thereafter but prior to [***].
ii. For sales in Region I during the period from [***] through [***], Earned Royalties, as defined in Exhibit A, will be modified as follows:
x. The [***] percent ([***]%) rate set forth in Paragraph 3 of Exhibit A shall be [***] adjusted to [***] percent ([***]%);
y. the Minimum Amount/Test set forth in Paragraph 4 of Exhibit A for the HIV Qualitative Assay field shall be US$[***], rather than US$[***]; and
z. the Minimum Amount/Test set forth in Paragraph 4 of Exhibit A for the HIV Quantitative Assay field shall be US$[***], rather than US$[***].
iii. On or within 10 days following January 1, 2005, Roche shall pay Chiron Fifty-Two Million United States Dollars (USD52,000,000) in cumulative Earned Royalties for sales made in Region I after January 1, 2005 and continuing through the life of the applicable CHIRON Licensed Patent(s). Subject to Section 5, such payment shall be nonrefundable. Upon this Term Sheet becoming binding on all of the parties pursuant to Section 10, the definition of "CHIRON Licensed Patents" in the Clinical Diagnostics Agreement shall be expanded to include the "Additional Chiron Patents." Subject to Sections 5 and 6, upon the payment of such amount, nothing further shall be due to Chiron from Roche in consideration of the licenses granted pursuant to Sections 2.1 and 2.3 of the Clinical Diagnostics Agreement for sales in Region I of CHIRON Licensed Products made after January 1, 2005.
iv. With respect to CHIRON Future HIV Sequence Patent Rights acquired by Chiron after [***] but prior to ("[***]"), pursuant to Section 2.5 of the Clinical Diagnostics Agreement, Chiron agrees to grant such rights to Roche on the following payment terms:
Royalty Provisions. (a) The Licensee shall pay the Licensor a Royalty percentage as described on the Schedule A of this Agreement. The Royalty shall be based on the Licensed Products' "Net Sales Price," as defined below. In calculating the Royalty payment, the following formula shall be used. Amount sold or distributed) less returns actually credited) multiplied by the Net Sales Price multiplied by the current royalty percentage equals the Royalty.
Royalty Provisions. All capitalized terms not otherwise defined in this Schedule F shall have the meanings ascribed to them in the Exclusive License Agreement to which this Schedule F is attached (the “Agreement”).
Royalty Provisions. Subject to the provisions of this Addendum, Atari shall pay as royalties on the Title the amounts identified as royalties in the Compensation Schedule (Exhibit D) of this Agreement.
Royalty Provisions. The LICENSEE agrees to pay to the LICENSOR the royalty amount specified in Exhibit B hereto. At the request of the LICENSEE, LICENSOR will consider in good faith a request by LICENSEE to modify the royalty payments due under this LICENSE based on a substantial change in business or market conditions. Additionally, upon written request by USEC, not later than sixty days before royalty payments become due and payable, DOE may approve a request to adjust the royalties due under the LICENSE in any given year: (1) where third parties assert a claim for patent infringement against USEC, the alleged infringement necessarily arises out of the practice of the DOE-owned licensed inventions and USEC incurs costs in defending against such claim; or (2) where USEC owes royalties to third parties for use of third party-owned patents that are necessary for the practice of the DOE-owned licensed inventions. Except as provided in this Section 6 there shall be no other royalty, fee, or other charge or cost due or payable by LICENSEE for this LICENSE or for the use of the LICENSED INVENTIONS or data provided under this LICENSE.
Royalty Provisions. This License is granted free of royalty or other payment obligations by LICENSEE.
Royalty Provisions royalty of the gross income and deemed receipts accruing to BBC Worldwide, its licensees and assigns, will be paid in respect of any commercial activity (unless there is a specific separate agreement which varies terms e.g. commercial audio release). In the case of operas, concerts and chart-type programmes featuring both MU and Equity artists a royalty of 25% will be paid in respect of sales. In both cases the royalty shall be shared in proportion to the artist’s aggregate fees in the programmes concerned.
